DISCOVERYBIOMED, INC.
Human taste-cell screening platform for identifying bitter taste blockers
- Sector
- Biotech
- Headquarters
- Birmingham, AL
- Total capital
- $9.4M
- Federal grants
- $9.4M
- 16 awards · 2015–2021
- Rank in peer group#1 of 36
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 13 pending · first 2017
- Rank in peer group#5 of 36
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Broad Spectrum Bitter Taste Antagonists Discovery$21K
- Federal grantHealth and Human S · Phase II · Broad Spectrum Bitter Taste Antagonists Discovery$765K
- Federal grantHealth and Human S · Phase II · Broad Spectrum Bitter Taste Antagonists Discovery$1.6M
- Federal grantHealth and Human S · Phase I · STING Inhibitor Discovery for Rare and Common Autoimmune Diseases$300K
- Federal grantHealth and Human S · Phase II · Humanized Kidney Cellular Toxicity Platforms$552K
- Federal grantHealth and Human S · Phase I · Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery$15K
- Federal grantHealth and Human S · Phase I · Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery$271K
Show 9 earlier federal awards
- Federal grantHealth and Human S · Phase II · Humanized Kidney Cellular Toxicity Platforms$1.1M
- Federal grantHealth and Human S · Phase II · Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia$385K
- Federal grantHealth and Human S · Phase II · Humanized Kidney Cellular Toxicity Platforms$206K
- Federal grantHealth and Human S · Phase II · Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia$839K
- Federal grantHealth and Human S · Phase II · Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development$2K
- Federal grantHealth and Human S · Phase II · Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development$799K
- Federal grantHealth and Human S · Phase II · Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia$366K
- Federal grantHealth and Human S · Phase II · DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease$632K
- Federal grantHealth and Human S · Phase II · Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development$1.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 36 peers
Line = medianBiotech · Platform
- Federal grants#1 · top 3%
- Granted patents#5 · top 14%
- Linked publications#1 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 4 granted of 17- PendingHuman Diseased And Normal Kidney Epithelial Cell Cultures And Uses ThereofUSPTOApplication 17615419
- GrantedCoumarin Derivatives And Methods Of Use In Treating Hyperproliferative DiseasesUSPTOUS 10,369,145
- GrantedCoumarin Derivatives And Methods Of Use In Treating Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, And Misfolded Protein DisordersUSPTOUS 9,815,825
Show all 17 patent records
- Human Diseased And Normal Kidney Epithelial Cell Cultures And Uses ThereofJul 28, 2022 · Application 17615419Pending
- Coumarin Derivatives And Methods Of Use In Treating Hyperproliferative DiseasesAug 6, 2019 · US 10,369,145Granted
- Coumarin Derivatives And Methods Of Use In Treating Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, And Misfolded Protein DisordersNov 14, 2017 · US 9,815,825Granted
- Small Molecule Cftr CorrectorsJun 13, 2017 · US 9,676,779Granted
- Small Molecule Bicyclic And Tricyclic Cftr CorrectorsJan 17, 2017 · US 9,546,176Granted
- Small Molecule Cftr CorrectorsApplication PCTUS2013070987Pending
- Small Molecule Bicyclic And Tricyclic Cftr CorrectorsApplication PCTUS2013070989Pending
- Coumarin Derivatives and Methods of Use in Treating Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, and Misfolded Protein DisordersApplication 61788353Pending
- Coumarin Derivatives and Methods of Use in Treating Hyperproliferative DiseasesApplication 61788398Pending
- Small Molecule CFTR CorrectorsApplication 61728414Pending
- Small Molecule Bicyclic and Tricyclic CFTR CorrectorsApplication 61728417Pending
- Methods Of Modulating Ires-mediated TranslationApplication PCTUS2010028917Pending
- Identifying Parathyroid Hormone Agonists And AntagonistsApplication PCTUS2009062818Pending
- Human Diseased And Normal Kidney Epithelial Cell Cultures And Uses ThereofApplication PCTUS2020034992Pending
- Human Diseased And Normal Kidney Epithelial Cell Cultures And Uses ThereofApplication 62854756Pending
- Coumarin Derivatives And Methods Of Use In Treating Hyperproliferative DiseasesApplication PCTUS2014027154Pending
- Coumarin Derivatives And Methods Of Use In Treating Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, And Misfolded Protein DisordersApplication PCTUS2014027079Pending
Recent research by its founders
- Local Delivery of rhBMP-2 Affects Systemic Metabolic Response During Healing of Critically-Sized Segmental Defects in a Rat Model20260 cites
- Metabolomics of Papanicolaou Tests for the Discovery of Ovarian Cancer Biomarkers20240 cites
- Inhibition of Bitter Taste from Oral Tenofovir Alafenamide202121 cites
Related companies, and why
- CurlBio LLCSimilar federal contract value in Biotech · null in contracts
- DMK PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- CHROMOCELL CORPORATIONSimilar federal contract value in Biotech · null in contracts
- PHOENICIA BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- REVEL TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- Syllable Life Sciences, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .